

Epigenetic Drugs & Diagnostics Market

<https://marketpublishers.com/r/E171401EC50EEN.html>

Date: June 2026

Pages: 0

Price: US\$ 4,950.00 (Single User License)

ID: E171401EC50EEN

Abstracts

Upcoming research reports. Delivery timeline: 4 weeks

The epigenetic drugs and diagnostics market includes treatments and diagnostic tools that target changes in gene expression without altering DNA sequences. This market covers DNA methylation inhibitors (e.g., azacitidine, decitabine), histone deacetylase (HDAC) inhibitors (e.g., vorinostat, romidepsin), and other emerging therapies used in cancer, neurological disorders, and autoimmune diseases. Increasing R&D investments, a focus on precision medicine, and growing funding are key factors driving market growth. Advances in next-generation sequencing (NGS) and biomarker-based diagnostics are also improving disease detection and personalized treatment approaches. There are opportunities in developing new epigenetic drugs that target enzymes like SETD2 (EZH2), LSD1, and BET proteins, expanding treatment options beyond cancer. However, market growth is limited by the off-target effects of epigenetic drugs, as their complex mechanisms are not yet fully understood. Despite these challenges, ongoing research and technological progress continue to advance this field.

Epigenetic Drugs & Diagnostics Market- Global Forecast to 2030

Global Epigenetics Drugs & Diagnostics Market Dynamics

Driver: Increasing research & investments supported by rising focus on precision medicines to drive growth

Increasing investments in epigenetics research, driven by the demand for personalized medicine, are key factors supporting the growth of the epigenetic drugs and diagnostics market. Initiatives such as the November 2024, partnership of Oxford Nanopore Technologies with UK Biobank aim to improve disease detection and treatment through large-scale epigenomic mapping. This project, sequencing 50,000 participant samples,

will help identify key methylation markers linked to various diseases. Similarly, in January 2025, researchers at the Johns Hopkins Kimmel Cancer Center and the Chinese Academy of Sciences explored a potential epigenetic therapy for colorectal cancer by targeting the UHRF1 protein using mRNA-based lipid nanoparticle technology.

Moreover, companies like Chroma Medicine are also advancing the field, securing USD 135 million in Series B financing to develop single-dose epigenetic editing therapies. Additionally, studies on DNA methyltransferase inhibitors (DNMTis) and EZH2 inhibitors (EZH2is) suggest that combining these therapies can improve treatment response in solid tumors by modifying the epigenomic landscape. Institutions like the University of Texas MD Anderson Cancer Center publish a high volume of studies relating to epigenetic therapies. Key research areas include drug resistance, immunotherapy, and combination therapies, emphasizing the need for optimized treatment strategies. With ongoing funding, research advancements, and new therapeutic approaches, the epigenetics market is expected to grow further.

Challenge: Limited understanding of epigenetic mechanism and off-target effects of epigenetic drugs, a major challenge to adoption

A key challenge in the epigenetic drugs and diagnostics market is the limited understanding of epigenetic mechanisms. There are gaps in knowledge about DNA and RNA modifications, reader domains, and protein interactions, making it difficult to identify effective drug targets. More research is needed to understand how these modifications influence diseases and treatment responses. Another challenge is the off-target effects of epigenetic drugs. Many of these drugs lack specificity and affect multiple enzymes, which can cause unintended side effects. To improve safety and effectiveness, precise drug delivery is essential. Advanced delivery systems like lipid nanoparticles are being explored to enhance targeting. Overcoming these challenges will require further research, better drug design, and improved delivery technologies.

Recent Developments in the Epigenetic Drugs and Diagnostics Market:

In January 2025, Tune Therapeutics raised USD 175 million in a Series B funding round to advance epigenetic editing therapies, which modify gene expression without DNA alteration. The therapy aims to silence viral DNA, preventing further virus production.

In January 2024, MoonWalk Biosciences, raised USD 57 million in seed and Series A funding from Alpha Wave Ventures, ARCH Venture Partners, Future Ventures, GV,

Khosla Ventures, and YK Bioventures. The funding will support the advancement of Moonwalk's epigenetic profiling and engineering platform and its therapeutic pipeline. The company aims to develop precision epigenetic medicines by targeting the epigenetic code.

In January 2024, Novo Nordisk entered into a partnership with Omega Therapeutics to develop novel treatments for cardiometabolic diseases. Omega's epigenomic controller technology will enhance thermogenesis and metabolic activity for obesity management.

Contents

1 INTRODUCTION

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

5 MARKET OVERVIEW

5.1 INTRODUCTION

5.2 MARKET DYNAMICS

5.2.1 DRIVERS

5.2.2 RESTRAINTS

5.2.3 OPPORTUNITIES

5.2.4 CHALLENGES

5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES

5.4 VALUE CHAIN ANALYSIS

5.5 SUPPLY CHAIN ANALYSIS

5.6 ECOSYSTEM ANALYSIS

5.7 TECHNOLOGY ANALYSIS

5.7.1 KEY TECHNOLOGIES

5.7.2 COMPLIMENTARY TECHNOLOGIES

5.7.3 ADJACENT TECHNOLOGIES

5.8 PORTER'S FIVE FORCES ANALYSIS

5.8.1 THREAT OF NEW ENTRANTS

5.8.2 THREAT OF SUBSTITUTES

5.8.3 BARGAINING POWER OF SUPPLIERS

5.8.4 BARGAINING POWER OF BUYERS

5.8.5 INTENSITY OF COMPETITION RIVALRY

5.9 REGULATORY ANALYSIS

5.9.1 REGULATORY BODIES, GOVERNMENT AGENCIES & OTHER ORGANIZATIONS

5.9.2 REGULATORY FRAMEWORK

5.10 PRICING ANALYSIS

5.11 KEY CONFERENCES AND EVENTS IN 2025-26

5.12 KEY STAKEHOLDERS & BUYING CRITERIA

5.12.1 KEY STAKEHOLDERS IN THE BUYING PROCESS

5.12.2 BUYING CRITERIA FOR END USERS

5.13 PATENT ANALYSIS

5.14 INVESTMENT AND FUNDING ACTIVITIES

5.15 IMPACT OF AI/GENERATIVE AI ON EPIGENETIC DRUGS & DIAGNOSTICS MARKET

6 EPIGENETIC DRUGS MARKET, BY DRUG CLASS

6.1 INTRODUCTION

6.2 DNA METHYLATION INHIBITORS

6.3 HISTONE MODIFICATION ENZYME INHIBITORS

6.4 ISOCITRATE DEHYDROGENASE (IDH) INHIBITORS

6.5 OTHER DRUG CLASSES

7 EPIGENETIC DRUGS MARKET, BY INDICATION

7.1 INTRODUCTION

7.2 ONCOLOGY

7.2.1 HEMATOLOGIC MALIGNANCIES

7.2.2 SOLID TUMORS

7.2.3 OTHER CANCERS

7.3 NON-ONCOLOGY

7.3.1 NEUROLOGICAL DISORDER

7.3.2 AUTOIMMUNE DISEASES

7.3.3 INFECTIOUS DISEASE

7.3.4 OTHER DISEASES

8 EPIGENETIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION

8.1 INTRODUCTION

8.2 ORAL

8.3 INTRAVENOUS

9 EPIGENETIC DIAGNOSTICS MARKET, BY TEST TYPE

9.1 INTRODUCTION

9.2 PCR ASSAYS

9.3 NGS ASSAYS

9.4 OTHERS

10 EPIGENETIC DIAGNOSTICS MARKET, BY PRODUCT TYPE

10.1 INTRODUCTION

10.2 REAGENTS & KITS

10.3 INSTRUMENTS

10.4 SOFTWARE & BIOINFORMATICS TOOLS

11 EPIGENETIC DRUGS & DIAGNOSTICS MARKET, BY END USER

11.1 INTRODUCTION

11.2 HOSPITAL

11.3 SPECIALTY CLINICS

11.4 RESEARCH INSTITUTES

12 EPIGENETIC DRUGS & DIAGNOSTICS MARKET, BY REGION

12.1 INTRODUCTION

12.2 NORTH AMERICA

12.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA

12.2.2 US

12.2.3 CANADA

12.3 EUROPE

12.3.1 MACROECONOMIC OUTLOOK FOR EUROPE

12.3.2 GERMANY

12.3.3 UK

12.3.4 FRANCE

12.3.5 ITALY

12.3.6 SPAIN

12.3.7 REST OF EUROPE

12.4 ASIA PACIFIC

12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC

12.4.2 CHINA

12.4.3 JAPAN

12.4.4 INDIA

12.4.5 AUSTRALIA

12.4.5 SOUTH KOREA

12.4.6 REST OF APAC

12.5 LATIN AMERICA

12.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA

12.5.1 BRAZIL

12.5.2 MEXICO

12.5.3 REST OF LATIN AMERICA

12.6 MIDDLE EAST

12.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST

12.7 AFRICA

12.6.1 MACROECONOMIC OUTLOOK FOR AFRICA

13 COMPETITIVE LANDSCAPE

13.1 INTRODUCTION

13.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2024

13.3 REVENUE SHARE ANALYSIS, 2022-2024

13.4 MARKET SHARE ANALYSIS, 2024

13.5 EPIGENETIC DRUGS MARKET: COMPANY EVALUATION MATRIX: KEY PLAYER, 2024

13.5.1 STARS

13.5.2 EMERGING LEADERS

13.5.3 PERVASIVE PLAYERS

13.5.4 PARTICIPANTS

13.6 COMPANY FOOTPRINT, KEY PLAYERS, 2024

13.6.1 COMPANY FOOTPRINT

13.6.2 DRUG CLASS FOOTPRINT

13.6.3 INDICATION FOOTPRINT

13.6 COMPANY EVALUATION MATRIX, PIPELINE COMPANIES, 2024

13.6.1 PROGRESSIVE COMPANIES

13.6.2 RESPONSIVE COMPANIES

13.6.3 DYNAMIC COMPANIES

13.6.4 STARTING BLOCKS

13.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024

13.6.5.1 DETAILED LIST OF PIPELINE COMPANIES

13.6.5.2 COMPETITIVE BENCHMARKING OF KEY EMERGING

PLAYERS/STARTUPS

13.7 EPIGENETIC DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX: KEY PLAYER, 2024

13.7.1 STARS

13.7.2 EMERGING LEADERS

- 13.7.3 PERVASIVE PLAYERS
- 13.7.4 PARTICIPANTS
- 13.8 COMPANY FOOTPRINT, KEY PLAYERS, 2024
 - 13.8.1 COMPANY FOOTPRINT
 - 13.8.2 REGIONAL FOOTPRINT
 - 13.8.3 TEST TYPE FOOTPRINT
- 13.8 COMPANY EVALUATION MATRIX, START-UPS/SMES, 2024
 - 13.8.1 PROGRESSIVE COMPANIES
 - 13.8.2 RESPONSIVE COMPANIES
 - 13.8.3 DYNAMIC COMPANIES
 - 13.8.4 STARTING BLOCKS
 - 13.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
 - 13.8.5.1 DETAILED LIST OF KEY STARTUPS/ SMES
 - 13.8.5.2 COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS
- 13.9 BRAND/PRODUCT COMPARATIVE ANALYSIS
- 13.10 VENDOR VALUATION AND FINANCIAL METRICS OF THE EPIGENETIC DRUGS MARKET
- 13.11 VENDOR VALUATION AND FINANCIAL METRICS OF THE EPIGENETIC DIAGNOSTICS MARKET
- 13.12 COMPETITIVE SCENARIO AND TRENDS
 - 13.12.1 PRODUCT APPROVALS/ LAUNCHES
 - 13.12.2 DEALS
 - 13.12.3 OTHER DEVELOPMENTS

14 COMPANY PROFILES

- 14.1 KEY PLAYERS (APPROVED DRUGS)
 - 14.1.1 BMS
 - 14.1.2 AstraZenca
 - 14.1.3 Ispen
 - 14.1.4 Merck & Co.
 - 14.1.5 Otsuka Pharmaceutical Co., Ltd
 - 14.1.6 ITF Therapeutics LLC
 - 14.1.7 Acrotech Biopharma
 - 14.1.8 Chipscreen Biosciences
 - 14.1.9 Secura Bio
 - 14.1.10 Servier
 - 14.1.11 Rigel

14.2 KEY PLAYERS (DIAGNOSTICS)

- 14.2.1 ABBOTT
- 14.2.2 THERMO FISHER SCIENTIFIC INC.
- 14.2.3 F. HOFFMANN-LA ROCHE LTD
- 14.2.4 QIAGEN
- 14.2.5 PROMEGA
- 14.2.6 TAKARA
- 14.2.7 NEW ENGLAND BIOLABS
- 14.2.8 AMOYDX
- 14.2.9 Quir?nsalud

14.3 OTHER PLAYERS (PIPELINE)

- 14.3.1 Eli Lilly and Company
- 14.3.2 Novartis
- 14.3.3 Novo Nordisk
- 14.3.4 Omega Therapeutics
- 14.3.5 Zenith Epigenetics.
- 14.3.6 nChromaBio
- 14.3.7 STORM Therapeutics LTD
- 14.3.8 K36 Therapeutics
- 14.3.9 Epic Bio
- 14.3.10 Inherent Biosciences
- 14.3.11 Evopoint Biosciences Co., Ltd
- 14.3.12 Epizyme, Inc.
- 14.3.13 Pfizer
- 14.3.14 Bayer

Note: Above list is an indicative list of companies. Details on business overview, financial information, product portfolio, recent developments, and MarketsandMarkets view (for top players) will be provided for ~25 companies. These details might not be captured in the case of unlisted companies. The list of players provided is tentative and subject to change during the research.

15 APPENDIX

15.1 DISCUSSION GUIDE

15.2 KNOWLEDGE STORE: MARKETSandMARKETS' SUBSCRIPTION PORTAL

15.3 AVAILABLE CUSTOMIZATIONS

15.4 RELATED REPORTS

15.5 AUTHOR DETAILS

Note: The given segmentation is tentative and subject to change during the course of

research.

I would like to order

Product name: Epigenetic Drugs & Diagnostics Market

Product link: <https://marketpublishers.com/r/E171401EC50EEN.html>

Price: US\$ 4,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/E171401EC50EEN.html>